Research reportBlockade of hippocampal M1 muscarinic receptors impairs working memory performance of rats
References (44)
- et al.
The hippocampus - What does it do?
Behav. Neural Biol.
(1992) - et al.
(±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
Neurosci. Lett.
(1989) - et al.
Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization
Life Sci.
(1982) - et al.
RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects
Biol. Psychiatry
(1987) - et al.
The effect of pirenzepine on spatial learning in the Morris water maze
Pharmacol. Biochem. Behav.
(1988) On the role of the hippocampus in learning and memory in the rat
Behav. Neural Biol.
(1993)- et al.
Working and reference memory in rats in the three-panel runway task following dorsal hippocampal lesions
Jpn. J. Pharmacol.
(1992) - et al.
Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain
Neuroscience
(1986) - et al.
Evidence for a preferential involvement of M1 muscarinic receptors in representational memory
Neurosci. Lett.
(1990) - et al.
Selectivity of pirenzepine in the central nervous system. II. differential effects of pirenzepine and scopolamine on performance of a representational memory task
Brain Res.
(1987)
Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1–Ch6)
Neuroscience
Methoctramine, a polymethylene tetraamine, differentiates three subtypes of muscarinic receptor in direct binding studies
Eur. J. Pharmacol.
Effect of the κ-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task
Eur. J. Pharmacol.
Deficits in working memory following inhibition of hippocampal nitric oxide synthesis in the rat
Brain Res.
Amygdaloid NMDA and muscarinic receptors involved in working memory performance of rats
Physiol. Behav.
Post-training injection of the acetylcholine M2 receptor antagonist AF-DX 116 improves memory
Brain Res.
Brain muscarinic receptor subtypes are differentially affected in Alzheimer's disease and Parkinson's disease
Brain Res.
Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat
Eur. J. Pharmacol.
Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections
Brain Res.
Elevation of hippocampal extracellular acetylcholine levels by methoctramine
Brain Res. Bull.
Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities
J. Neurol. Sci.
Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
J. Neurochem.
Cited by (68)
The restructuring of muscarinic receptor subtype gene transcripts in c-fos knock-out mice
2013, Brain Research BulletinCitation Excerpt :Muscarinic receptors play important roles in many CNS functions in humans (Ellis et al., 2006) and experimental animals (Bymaster et al., 1993), and these functions have been further confirmed using knock-out studies (Wess, 2003; Wess et al., 2003, 2007). Regarding specific muscarinic receptor subtypes, M1 (Yamasaki et al., 2010), M2 and M4 (Ohno et al., 1994; Tzavara et al., 2003) have been implicated in attention, arousal and cognitive processes. M2 receptors mediate whole body tremor, hypothermia and analgesia (Gomeza et al., 2001).
Dissociation between memory reactivation and its behavioral expression: Scopolamine interferes with memory expression without disrupting long-term storage
2012, Neurobiology of Learning and MemoryDifferential effects of m1 and m2 receptor antagonists in perirhinal cortex on visual recognition memory in monkeys
2012, Neurobiology of Learning and MemoryCitation Excerpt :A probe test conducted twice in one animal with a much higher dose of methoctramine was also without effect: a mean error rate of 8% after infusing 10.0 mM of the drug vs. 9% after infusing saline. However, according to the in vitro binding data of Buckley et al. (1989), as well as the in vivo findings noted by Ohno et al. (1994), a concentration of methoctramine this high would be nonselective, and so we did not pursue testing this dose in the other animals). Two studies in rodents showed that insular cortex infusions of similar doses of pirenzepine (100 mM) and scopolamine (136–156 mM) led to similar levels of deficit in a conditioned taste aversion task (Naor & Dudai, 1996; Ramirez-Lugo, Miranda, Escobar, Espinosa, & Bermudez-Rattoni, 2003).
The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies
2010, Neuroscience and Biobehavioral ReviewsA role for protein kinase A and protein kinase Mζ in muscarinic acetylcholine receptor-initiated persistent synaptic enhancement in rat hippocampus in vivo
2008, NeuroscienceCitation Excerpt :Since medial septum cholinergic neurons are spontaneously active in the anesthetized rat there should be sufficient background source of ACh to tonically activate terminal autoreceptors (Apartis et al., 1998; Brazhnik and Fox, 1999). Indeed blockade of cholinergic autoreceptors by muscarinic receptor antagonists increases ACh release both in awake and anesthetized animals (Dudar, 1977; Stillman et al., 1993, 1996; Ohno et al., 1994; Quirion et al., 1995; Vannucchi et al., 1997; Carey et al., 2001). At some cholinergic synapses where there is tonic inhibition of ACh release via M2 receptors there is strong evidence that the activity-dependent initiation and termination of transmitter release is normally controlled by voltage-dependent regulation of the receptor’s coupling to key exocytotic machinery proteins and its affinity for ACh (Parnas and Parnas, 2007).